Evidence map›Paper›PMID 34669222›Full record

ArticleWound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society2021

Valsartan nano-filaments alter mitochondrial energetics and promote faster healing in diabetic rat wounds.

Lolita S Nidadavolu, David Stern, Ran Lin, Yuzhu Wang, Yi Li, Yuqiong Wu, Sela Marin, Marjorie J Antonio, Gayane Yenokyan, Tatiana Boronina and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Potential use of angiotensin receptor blockers in skin pathologies.Iranian journal of basic medical sciences · 2023
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Lolita S NidadavoluDivision of Geriatrics and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
David SternDepartment of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
Ran LinDepartment of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
Yuzhu WangDepartment of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
Yi LiDepartment of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
Yuqiong WuDivision of Geriatrics and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Sela MarinDivision of Geriatrics and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Marjorie J AntonioDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Gayane YenokyanJohns Hopkins Biostatistics Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Tatiana BoroninaMass Spectrometry and Proteomics Facility, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Robert ColeMass Spectrometry and Proteomics Facility, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
D Brian FosterDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Conover TalbotInstitute for Basic Biomedical Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-3758-2425
Jaroslaw JedrychDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Barbara SmithCell Biology Imaging Facility, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
David RiniDepartment of Art as Applied to Medicine, Division of Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Anne LeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Honggang CuiDepartment of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
Jeremy D WalstonDivision of Geriatrics and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Peter M AbadirDivision of Geriatrics and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-8186-0066
Johns Hopkins University · US

Funding

Technological Assessment and Solutions Core - RC4P30AG021334 · NIA · JOHNS HOPKINS UNIVERSITY · PI Jeremy D Walston · 2003 to 2026
$33.2M
Translational Aging Research Training ProgramT32AG058527 · NIA · JOHNS HOPKINS UNIVERSITY · PI Peter M. Abadir, Esther Seunghee Oh · 2018 to 2026
$4.0M
Age Related Change in Mitochondrial Angiotensin System and Mitochondrial DeclineR01AG046441 · NIA · JOHNS HOPKINS UNIVERSITY · PI ABADIR, PETER M. · 2014 to 2018
$2.3M
Thermo-Scientific Q Exactive Plus Orbitrap LC-MS/MS SystemS10OD025226 · OD · JOHNS HOPKINS UNIVERSITY · PI LE, ANNE · 2018 to 2018
$562k
LSM880 Laser-scanning Microscope with Airyscan ModuleS10OD023548 · OD · JOHNS HOPKINS UNIVERSITY · PI KUO, SCOT CHARLES · 2018 to 2018
$439k
NIA NIH HHS P30 AG021334NIA NIH HHS R01 AG046441NIA NIH HHS T32 AG058527NIH HHS S10 OD023548NIH HHS S10 OD025226
6 · The paper itself

Abstract

Chronic wounds are a common and debilitating condition associated with aging populations that impact more than 6.5 million patients in the United States. We have previously demonstrated the efficacy of daily topical 1% valsartan in treating wounds in diabetic mouse and pig models. Despite these promising results, there remains a need to develop an extended-release formulation that would reduce patient burden by decreasing the frequency of daily applications. Here, we used nanotechnology to self-assemble valsartan amphiphiles into a filamentous structure (val-filaments) that would serve as a scaffold in wound beds and allow for steady, localised and tunable release of valsartan amphiphiles over 24 days. Two topical treatments of this peptide-based hydrogel on full-thickness wounds in Zucker Diabetic Fatty rats resulted in faster rates of wound closure. By day 23, all val-filament treated wounds were completely closed, as compared to one wound closed in the placebo group. Mechanistically, we observed enrichment of proteins involved in cell adhesion and energetics pathways, downregulation of Tgf-β signalling pathway mediators (pSmad2, pSmad3 and Smad4) and increased mitochondrial metabolic pathway intermediates. This study demonstrates the successful synthesis of a sustained-release valsartan filament hydrogel, its impact on mitochondrial energetics and efficacy in treating diabetic wounds.

Indexed as

Diabetes MellitusWound HealingAnimalsHumansHydrogelsRatsRats, ZuckerValsartanHydrogelsValsartanangiotensinnanomedicinevalsartanwounds

Identifiers

PMID34669222
PMCPMC8571056
OpenAlexW3207927598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.